{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T20:07:58Z","timestamp":1784318878767,"version":"3.55.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K08478"],"award-info":[{"award-number":["21K08478"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Adenosine deaminase acting on RNA1 (ADAR1) is an interferon-inducible RNA-editing enzyme involved in the regulation of interferon signalling pathways. Although increased ADAR1 expression has been reported in systemic lupus erythematosus (SLE), the presence and clinical significance of anti-ADAR1 antibodies remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum samples from patients with SLE, idiopathic inflammatory myopathy (IIM), and rheumatoid arthritis (RA) were analysed. Anti-ADAR1 antibodies were quantified using a newly developed enzyme-linked immunosorbent assay, and specificity was confirmed by inhibition testing. Clinical and serological features were compared between antibody-positive and -negative patients. Hierarchical clustering and logistic regression analyses were performed to identify patient subsets and associated clinical features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Anti-ADAR1 antibodies were detected in 38 of 76 patients with SLE (50.0%), 29 of 130 with IIM (22.3%), and 2 of 22 with RA (9.0%). In SLE, patients with anti-ADAR1 antibodies more frequently exhibited pericarditis, myocarditis, splenomegaly, elevated immunoglobulin G levels, and positivity for anti-U1ribonucleoprotein, anti-Sm, and anti-Sj\u00f6gren's-syndrome-related antigen A antibodies. Cluster analysis identified three subgroups, with anti-ADAR1 antibodies enriched in a subset characterized by co-occurrence of autoantibodies against RNA-binding proteins. Exploratory analyses suggested that some clinical features showed different patterns of association with anti-ADAR1 antibody positivity and Cluster 3 membership.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Anti-ADAR1 antibodies are frequently detected in SLE and IIM, but are rare in RA. These antibodies are enriched in a subset of SLE cases characterized by coordinated production of antibodies against RNA-binding proteins within an interferon-related immunological context. These findings suggest that anti-ADAR1 antibodies may contribute to immunological stratification of SLE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roag056","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T20:05:03Z","timestamp":1782590703000},"source":"Crossref","is-referenced-by-count":0,"title":["Autoantibodies against adenosine deaminase acting on RNA1 in patients with systemic lupus erythematosus: Its relationship to clinical features and other autoantibodies"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2900-2344","authenticated-orcid":false,"given":"Sara","family":"Komatsu","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Dokkyo Medical University , Mibu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-7556","authenticated-orcid":false,"given":"Kazuhiro","family":"Kurasawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dokkyo Medical University , Mibu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dokkyo Medical University , Mibu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7631-8648","authenticated-orcid":false,"given":"Tomoka","family":"Hiyama","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dokkyo Medical University , Mibu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dokkyo Medical University , Mibu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3415-6260","authenticated-orcid":false,"given":"Yuhi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dokkyo Medical University , Mibu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3667-2721","authenticated-orcid":false,"given":"Anna","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dokkyo Medical University , Mibu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7933-8782","authenticated-orcid":false,"given":"Tomoyuki","family":"Miyao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dokkyo Medical University , Mibu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0021-2728","authenticated-orcid":false,"given":"Ayae","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dokkyo Medical University , Mibu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7682-0969","authenticated-orcid":false,"given":"Satoko","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dokkyo Medical University , Mibu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3584-0129","authenticated-orcid":false,"given":"Reika","family":"Maezawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dokkyo Medical University , Mibu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5169-7536","authenticated-orcid":false,"given":"Masafumi","family":"Arima","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dokkyo Medical University , Mibu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0574-9611","authenticated-orcid":false,"given":"Kei","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dokkyo Medical University , Mibu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"2026071716020497500_ref1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrm.2015.4","article-title":"A-to-I editing of coding and non-coding RNAs by ADARs","volume":"17","author":"Nishikura","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026071716020497500_ref2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.immuni.2015.11.001","article-title":"Isoforms of RNA-editing enzyme ADAR1 independently control nucleic acid sensor MDA5-driven autoimmunity and multi-organ development","volume":"43","author":"Pestal","year":"2015","journal-title":"Immunity."},{"key":"2026071716020497500_ref3","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.tibs.2021.02.002","article-title":"ADAR RNA modifications, the epitranscriptome and innate immunity","volume":"46","author":"Quin","year":"2021","journal-title":"Trends Biochem Sci"},{"key":"2026071716020497500_ref4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41577-023-00940-3","article-title":"Novel insights into double-stranded RNA-mediated immunopathology","volume":"24","author":"Reuver","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"2026071716020497500_ref5","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.2414","article-title":"Mutations in ADAR1 cause Aicardi-Gouti\u00e8res syndrome associated with a type I interferon signature","volume":"44","author":"Rice","year":"2012","journal-title":"Nat Genet"},{"key":"2026071716020497500_ref6","first-page":"575","article-title":"Emerging concepts of type I interferons in SLE pathogenesis and therapy","volume":"18","author":"Psarras","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2026071716020497500_ref7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"TULIP-2 trial investigators. Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"2026071716020497500_ref8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/BOR.0000000000000922","article-title":"An update on autoantibodies in systemic lupus erythematosus","volume":"35","author":"G\u00f3mez-Ba\u00f1uelos","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"2026071716020497500_ref9","doi-asserted-by":"crossref","first-page":"833114","DOI":"10.3389\/fmed.2021.833114","article-title":"Pathogenesis of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a concise review with an emphasis on type I interferon system","volume":"8","author":"Hu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026071716020497500_ref10","doi-asserted-by":"crossref","first-page":"1165225","DOI":"10.3389\/fmed.2023.1165225","article-title":"Interferon and autoantigens: intersection in autoimmunity","volume":"10","author":"Antiochos","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026071716020497500_ref11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000527008","article-title":"IRF1 is required for MDA5 (IFIH1) induction by IFN-\u03b1, LPS, and poly(I:C) in murine macrophages","volume":"15","author":"Aparici-Herraiz","year":"2023","journal-title":"J Innate Immun"},{"key":"2026071716020497500_ref12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s10875-007-9157-0","article-title":"Interferon-\u03b1 induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies","volume":"28","author":"Strandberg","year":"2008","journal-title":"J Clin Immunol"},{"key":"2026071716020497500_ref13","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/art.21893","article-title":"Induction of interferon-\u03b1 by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sj\u00f6gren\u2019s syndrome autoantigen-associated RNA","volume":"54","author":"L\u00f6vgren","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2026071716020497500_ref14","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1002\/art.22860","article-title":"A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro52\/anti-Ro60 autoantibodies","volume":"56","author":"Eloranta","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2026071716020497500_ref15","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-\u03b1 pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2026071716020497500_ref16","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0140-6736(02)09966-X","article-title":"Transcript mutations of the alpha regulatory subunit of protein kinase A and up-regulation of the RNA-editing gene transcript in lupus T lymphocytes","volume":"360","author":"Laxminarayana","year":"2002","journal-title":"Lancet."},{"key":"2026071716020497500_ref17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/ar1015","article-title":"Microarray analysis of gene expression in lupus","volume":"5","author":"Crow","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"2026071716020497500_ref18","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026071716020497500_ref19","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for idiopathic inflammatory myopathies and their subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026071716020497500_ref20","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2026071716020497500_ref21","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum"},{"key":"2026071716020497500_ref22","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","article-title":"Validation of the DAS28 and EULAR response criteria based on C-reactive protein against disease progression in rheumatoid arthritis","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026071716020497500_ref23","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","article-title":"BILAG 2004: development and initial validation of an updated version of the British Isles Lupus Assessment Group\u2019s disease activity index","volume":"44","author":"Isenberg","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"2026071716020497500_ref24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdermsci.2020.08.008","article-title":"Clinical and serological features of dermatomyositis and systemic lupus erythematosus patients with autoantibodies to ADAR1","volume":"100","author":"Muro","year":"2020","journal-title":"J Dermatol Sci"},{"key":"2026071716020497500_ref25","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"2026071716020497500_ref26","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/art.21890","article-title":"Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies","volume":"54","author":"Hua","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2026071716020497500_ref27","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with SLE, myositis, RA, and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026071716020497500_ref28","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1002\/art.21414","article-title":"Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus?","volume":"52","author":"To","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2026071716020497500_ref29","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/rheumatology\/kes261","article-title":"Relationship between autoantibody clustering and clinical subsets in SLE: cluster and association analyses in Hong Kong Chinese","volume":"52","author":"Li","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"2026071716020497500_ref30","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3899\/jrheum.130984","article-title":"Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center","volume":"41","author":"Artim-Esen","year":"2014","journal-title":"J Rheumatol"},{"key":"2026071716020497500_ref31","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/ard-2022-223808","article-title":"Machine learning identifies clusters of longitudinal autoantibody profiles predictive of SLE disease outcomes","volume":"82","author":"Choi","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026071716020497500_ref32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/mr\/roac010","article-title":"The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026071716020497500_ref33","doi-asserted-by":"crossref","first-page":"e000221","DOI":"10.1136\/lupus-2017-000221","article-title":"Associates and predictors of pleurisy or pericarditis in SLE","volume":"4","author":"Ryu","year":"2017","journal-title":"Lupus Sci Med"},{"key":"2026071716020497500_ref34","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/ard.49.8.627","article-title":"Possible association between anti-Ro antibodies and myocarditis or cardiac conduction defects in adults with SLE","volume":"49","author":"Logar","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"2026071716020497500_ref35","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/rheumatology\/keae376","article-title":"Distinctive clinical traits of lupus-related myocarditis: a multicenter retrospective study","volume":"64","author":"Ramirez","year":"2025","journal-title":"Rheumatology (Oxford)"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag056\/68633505\/roag056.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag056\/68633505\/roag056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T20:02:11Z","timestamp":1784318531000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/advance-article\/doi\/10.1093\/mr\/roag056\/8719637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":35,"URL":"https:\/\/doi.org\/10.1093\/mr\/roag056","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"article-number":"roag056"}}